LIGAND PHARMACEUTICALS INCORPORATED LGND Income Statement

Ligand pharmaceuticals incorporated (LGND)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
Total revenues
109,959	120,282	152,869	173,724	238,780	251,453	242,328	230,040	167,992	141,102	128,822	117,066	108,592	108,973	91,981	88,063	86,960	71,914	73,720	70,992	63,182	64,538	56,276	54,308	53,280	48,973	47,871	41,241	37,403	31,388	30,690	30,056	31,777	30,037	24,902	24,999	0	0	0
Operating costs and expenses:
Cost of Captisol
12,172	11,347	12,365	10,678	9,407	6,337	5,119	6,044	5,813	5,366	6,526	5,140	4,957	5,571	3,557	3,808	5,688	5,807	8,927	9,173	7,759	9,136	6,450	7,492	7,520	5,732	6,743	4,888	4,109	3,601	3,331	3,351	4,539	4,909	0	0	0	-	0
Amortization of intangibles
16,896	16,864	14,044	16,217	16,017	15,792	16,301	13,282	12,683	12,120	10,859	10,859	10,834	10,643	8,505	6,392	4,305	2,375	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
56,510	55,908	46,082	37,823	31,745	27,863	27,658	26,934	25,621	26,887	24,659	25,798	25,890	21,221	17,092	13,139	11,641	11,005	9,635	10,711	9,984	9,747	11,214	10,607	9,940	9,274	9,377	9,610	10,438	10,790	10,911	10,735	11,122	10,291	12,629	16,760	0	0	0
General and administrative
40,060	41,884	42,771	42,879	41,179	37,734	34,320	31,719	28,974	28,653	27,700	27,218	27,906	27,653	28,064	26,485	26,473	25,398	23,707	25,478	23,492	22,570	21,473	19,487	18,554	17,984	17,766	17,316	16,868	15,782	14,901	14,557	14,554	14,583	14,336	13,664	0	0	0
Lease exit and termination costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,348	1,185	1,103	1,084	722	767	675	560	717	654	1,024	1,022	1,386	1,220	790	552	15,725	15,727	0	0	0
Write-off of acquired IPR&D
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	-	-	-	-
Total operating costs and expenses
125,638	126,003	115,262	107,597	98,348	87,726	83,398	77,979	73,091	73,026	69,744	69,015	69,587	65,088	56,432	49,383	47,884	44,585	47,773	50,110	45,307	44,912	39,859	38,353	37,169	34,030	35,083	32,948	32,439	31,195	30,529	32,145	33,287	32,617	47,823	48,299	0	0	0
Gain from sale of Promacta license
0	812,797	812,797	812,797	812,797	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of deferred gain on sale leaseback
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,702	1,704	1,704	0	0	0
Income from operations
-15,679	807,076	850,404	878,924	953,229	163,727	158,930	152,061	94,901	68,076	59,078	48,051	39,005	43,885	35,549	38,680	39,076	27,329	25,947	20,882	17,875	19,626	16,417	15,955	16,111	14,943	12,788	8,293	4,964	193	585	-1,239	-234	-878	-21,217	-21,596	0	0	0
Other income (expense):
Increase in contingent liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-2,168	-	-2,633	626	-6,316	-5,013	-5,231	-9,152	-3,190	-5,135	-8,845	-7,757	-3,704	-3,597	-2,473	152	-4,004	-1,650	1,493	-798	1,788	-1,013	1,145	5,033	0	0	0
Gain (loss) from Viking
-39,862	2,888	-78,863	-5,945	46,383	50,187	124,912	61,495	20,132	-2,048	-12,495	-12,872	-22,610	-23,132	-16,243	-17,016	-6,748	-5,143	-3,039	-870	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
27,251	28,430	27,478	25,556	19,033	13,999	9,675	4,682	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Interest expense
35,387	35,745	47,053	49,260	53,702	48,276	31,926	24,112	13,999	13,460	13,338	13,068	12,778	12,842	-11,502	-11,688	-11,770	-11,802	2,067	653	-2,135	-4,860	-1,891	-3,013	-2,741	-2,077	-3,363	-3,022	-2,713	-2,924	-1,895	-1,931	-2,019	-2,297	1,804	1,118	0	0	0
Gain on deconsolidation of Viking
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other expense, net
-12,812	-6,010	-3,939	-2,151	-4,212	-6,307	-1,398	-1,171	2,241	2,603	-3,617	-1,821	-865	-615	1,987	2,257	2,606	1,768	2,432	1,452	1,978	1,671	990	366	-1,008	-63	319	453	453	516	831	806	836	630	1,798	1,976	0	0	0
Total other income (loss), net
-60,810	-10,437	-102,377	-31,800	7,502	9,603	101,854	41,568	11,449	-10,845	-25,285	-25,118	-34,423	-35,925	-28,991	-26,049	5,898	8,000	10,565	9,247	-8,797	-8,324	-10,118	-8,532	-6,125	-5,737	-4,639	-2,221	-6,686	-4,058	-412	-2,692	12	-2,680	1,235	6,105	0	0	0
Income (loss) before income taxes
-76,489	796,639	748,027	847,124	960,731	173,330	260,784	193,629	106,350	57,231	33,793	22,933	4,582	7,960	6,558	12,631	44,974	35,329	36,512	30,129	9,078	11,302	6,299	7,423	9,986	9,206	8,149	6,072	-1,722	-3,865	173	-3,931	-222	-3,558	-19,982	-15,491	0	0	0
Income tax benefit (expense)
-15,323	167,337	153,840	170,324	196,352	30,009	81,990	73,771	53,594	44,675	17,355	13,870	7,747	10,327	-541	-192,582	-188,436	-192,115	-191,321	684	372	410	268	204	361	374	-1,400	-1,318	-1,090	-1,191	742	622	425	-13,270	-13,148	-12,545	0	0	0
Income (loss) from operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-2,367	7,099	205,213	233,410	227,444	0	0	0	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Discontinued operations:
Net income from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-632	-2,674	-569	-4,553	-647	9,712	-6,834	-2,946	0	0	0
Gain on sale of Oncology Product Line before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	1,139	1,139	1,139	1,139	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense on discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	400	408	408	408	0	0	0	0	-	-	-	-	-	-	-	-	1,509	-14	-14	0	-	0	0	-	-	-
Income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,588	2,588	2,588	1,799	3,656	0	0	0	-	-	-	-	-	-
Income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	1,065	1,065	467	2,147	3,669	3,669	1,870	3	16	23	0	0	0
Net income (loss) including noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	227,444	227,833	29,445	8,706	10,892	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Less: Net loss attributable to noncontrolling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,380	-2,705	-3,208	-1,975	-1,132	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-61,166	629,302	594,187	676,800	764,379	143,321	178,794	119,858	52,756	12,556	16,438	9,063	-3,165	-1,636	7,830	205,944	235,678	229,824	230,538	32,653	10,681	12,024	6,838	7,523	12,022	11,420	10,614	8,455	-165	-527	3,100	-884	1,223	9,715	-6,818	-2,923	0	0	0
Earnings Per Share [Abstract]
Earnings Per Share, Basic and Diluted:
Income (loss) from continuing operations (USD per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.14	0.05	-0.30	0.28	0.37	10.01	1.19	0.04	-	-	-	-	0.09	0.10	0.18	0.06	0.13	-0.01	-0.22	-0.04	0.23	-0.21	-0.02	0.49	-0.60	-0.01
Income from discontinued operations (USD per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	-	-	-	-	0.00	0.00	0.12	0.01	-	0.00	0.09	-	-	-	-	-	-	-
Basic net income (loss) per share (USD per share)
-1.46	2.09	-0.81	-0.74	32.59	-2.00	3.19	3.45	2.13	-0.33	0.40	0.29	0.24	-0.15	0.05	-0.30	0.32	0.37	10.01	1.19	0.04	-	0.06	0.08	-	0.09	0.10	0.30	0.07	-	-0.01	-0.13	-	-	-	-	-	-	-
Weighted average common shares outstanding:
Discontinued operations (in usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.10	-	0.00	0.00	-	-	0.00
Basic and diluted net income per share (in usd per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.10	-	-	-	-	-	-	-	0.06	-	-0.21	-0.02	0.49	-0.60	-0.01
Shares used in basic per share calculations (shares)
16,529	17,205	18,770	19,558	20,447	21,071	21,148	21,212	21,209	21,106	21,071	21,013	20,938	20,897	20,887	20,832	20,708	19,936	19,887	19,725	19,612	19,919	20,417	20,738	20,600	20,444	20,357	20,258	20,189	20,036	19,917	19,749	19,709	-	19,673	19,650	-	19,629	19,608
Diluted per share amounts:
Income (loss) from continuing operations (USD per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	0.05	-0.30	0.26	0.40	9.28	1.11	0.04	-	-	-	-	0.10	0.09	0.18	0.06	-	-0.01	-0.22	-	-	-	-	-	-	-
Income from discontinued operations (USD per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.00	0.00	0.03	0.00	0.00	0.00	0.00	-	-	-	-	-0.01	0.00	0.12	0.01	-	0.00	0.09	-	-	-	-	-	-	-
Diluted net income (loss) per share (USD per share)
-1.46	2.08	-0.81	-0.74	31.32	-1.66	2.80	2.99	1.83	-0.31	0.36	0.26	0.22	-0.13	0.05	-0.30	0.30	0.40	9.28	1.11	0.04	-	0.06	0.07	-	0.09	0.09	0.30	0.07	-	-0.01	-0.13	-	-	-	-	-	-	-
Shares used in diluted per share calculations (shares)
16,529	19,423	18,770	19,558	21,277	22,978	24,052	24,438	24,800	24,137	23,551	23,215	23,019	17,210	22,997	20,831	22,283	21,545	21,459	21,276	20,630	21,398	21,345	21,780	21,208	21,430	20,843	20,427	20,280	20,006	19,917	19,749	19,738	19,906	19,673	19,650	19,623	19,629	19,608
Royalties
Total revenues
34,003	46,976	76,144	102,504	127,274	128,556	116,656	102,460	85,275	88,685	79,953	73,720	69,263	59,423	51,388	45,445	42,297	38,194	36,069	33,796	32,431	29,994	27,691	25,933	25,608	23,584	21,283	18,772	16,839	14,073	11,873	11,091	10,280	9,213	8,370	7,540	0	0	0
Captisol
Total revenues
43,639	31,489	34,450	34,628	33,691	29,123	26,765	27,402	25,340	22,070	23,391	19,946	18,282	22,502	20,652	22,479	29,274	27,662	33,419	33,707	26,502	28,488	22,337	22,731	23,248	19,072	17,542	12,632	10,304	9,432	10,591	10,452	11,771	12,123	0	0	0	-	0
Service revenue
Total revenues
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract revenue
Total revenues
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License fees, milestones and other revenues
Total revenues
-	-	42,275	36,592	-	93,774	98,907	100,178	57,377	30,347	25,478	23,400	21,047	27,048	19,941	20,139	15,389	6,058	4,232	3,489	4,249	6,056	6,248	5,644	4,424	6,317	9,046	9,837	10,260	7,883	8,226	8,513	9,726	8,701	10,850	13,456	0	0	0